Disseminated Mucormycosis: When First-Line Antifungal Therapy Does Not Achieve Disease Control
This protocol applies to patients with disseminated mucormycosis whose initial treatment — combining surgical debridement and systemic antifungal therapy — has not produced adequate disease control. It defines the evidence-based next step when escalation is required.
Previous Line — Failure Condition
First-line treatment — early complete surgical debridement together with immediate systemic antifungal therapy — did not achieve the required goal: stable disease or partial response, with resolution of signs and symptoms of infection and substantial radiographical improvement on weekly imaging assessment.
This failure to meet first-line targets is the trigger for escalation to the salvage approach described here.
Salvage Approach (Partial Overview)
The recommended strategy involves switching to a different antifungal class. Several antifungal options are available, with selection guided by disease course, extent of progression, and the patient's overall condition. Combination approaches may also apply in specific clinical circumstances. The complete regimen — including agent selection, sequencing, and escalation criteria — is outlined in the full structured protocol.
Treatment Goal
Stable disease or partial response, with resolution of signs and symptoms of infection and substantial radiographical improvement on imaging.
References
- Isavuconazole is strongly supported as salvage treatment.
- Posaconazole delayed release tablets or infusions are strongly supported for salvage treatment, and when available should be preferred over posaconazole oral suspension, which in turn is marginally supported for salvage treatment.
- In cases of primary treatment failure with isavuconazole or posaconazole, the guideline group supports recommendations for all three lipid-based amphotericin B formulations with strong to moderate strength.
- In case of extensive disease, rapid progression, or poor general condition, the addition of isavuconazole or posaconazole can be considered.
- Limited data support combinations of polyenes and azoles or polyenes plus echinocandins.
- Therapy can be continued until resolution of signs and symptoms of infection, and substantial radiographical improvement.
View source ↗